{
    "organizations": [],
    "uuid": "7c6df102ab2115de09a27c0ff32defa1a0ca7d51",
    "author": "",
    "url": "https://www.reuters.com/article/brief-kadmon-receives-fda-guidance-on-pi/brief-kadmon-receives-fda-guidance-on-pivotal-clinical-trial-design-for-kd025-in-chronic-graft-versus-host-disease-idUSASC09VDZ",
    "ord_in_thread": 0,
    "title": "BRIEF-Kadmon Receives FDA Guidance On Pivotal Clinical Trial Design For KD025 In Chronic Graft-Versus Host Disease",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 10, 2018 / 12:02 PM / Updated 8 minutes ago BRIEF-Kadmon Receives FDA Guidance On Pivotal Clinical Trial Design For KD025 In Chronic Graft-Versus Host Disease Reuters Staff \nApril 10 (Reuters) - Kadmon Holdings Inc: * HOST DISEASE \n* ARM, PIVOTAL PHASE 2 CLINICAL TRIAL TO SUPPORT POTENTIAL REGISTRATION OF KD025 IN CGVHD Source text for Eikon: Further company coverage:",
    "published": "2018-04-10T15:01:00.000+03:00",
    "crawled": "2018-04-10T15:17:04.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "receives",
        "fda",
        "guidance",
        "pivotal",
        "clinical",
        "trial",
        "design",
        "kd025",
        "chronic",
        "host",
        "disease",
        "reuters",
        "staff",
        "april",
        "reuters",
        "kadmon",
        "holding",
        "inc",
        "host",
        "disease",
        "arm",
        "pivotal",
        "phase",
        "clinical",
        "trial",
        "support",
        "potential",
        "registration",
        "kd025",
        "cgvhd",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}